靶向癌症治疗腹腔内不良反应的分子与临床路径
本文提出将靶向癌症治疗的腹腔内不良反应按分子机制分为四类:1类为与治疗反应相关的靶向不良反应;2类为与治疗反应无关的靶向不良反应;3类为脱靶不良反应;4类为肿瘤坏死相关不良反应。理解这些分子机制有助于放射科医生识别不良反应、将其与肿瘤进展区分,并指导肿瘤医生管理不良反应及决定是否继续用药。
要点
- 靶向治疗腹腔不良反应按分子机制分四类,有助于与肿瘤进展鉴别。
- 了解分子机制与治疗反应的关联,可更有效识别不良反应并指导临床决策。
- 本文以典型病例图像展示已确立或推测的分子机制相关不良反应。
核心结论
- 放射科医生应采用整合分子机制与临床结局的概念框架来归类靶向治疗不良反应,而非传统器官系统方法。
研究设计与样本
- 本文为综述,聚焦腹腔和盆腔靶向治疗不良反应,按已确立或推测的分子机制分类,并以典型病例图像展示。
关键影像表现/征象
- 靶向治疗不良反应可分为四类:1类为与治疗反应相关的靶向不良反应;2类为与治疗反应无关的靶向不良反应;3类为脱靶不良反应;4类为肿瘤坏死相关不良反应。
临床应用与阅片要点
- 理解不良反应的分子机制及其与治疗反应的已知关联,有助于放射科医生识别不良反应并与肿瘤进展区分。
- 放射科医生可据此更有效指导肿瘤医生管理不良反应及决定继续或停止药物治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Targeted cancer therapies encompass an exponentially growing number of agents that involve a myriad of molecular pathways. To excel within this rapidly changing field of clinical oncology, radiologists must eschew traditional organ system-based approaches of cataloging adverse effects in favor of a conceptual framework that incorporates molecular mechanisms and associated clinical outcomes. Understanding molecular mechanisms that underlie imaging manifestations of adverse effects and known associations with treatment response allows radiologists to more effectively recognize adverse effects and differentiate them from tumor progression. Radiologists can therefore more effectively guide oncologists in the management of adverse effects and treatment decisions regarding continuation or cessation of drug therapy. Adverse effects from targeted cancer therapies can be classified into four categories: (a) category 1, on-target adverse effects associated with treatment response; (b) category 2, on-target adverse effects without associated treatment response; (c) category 3, off-target adverse effects; and (d) category 4, tumor necrosis-related adverse effects. This review focuses on adverse effects primarily within the abdomen and pelvis classified according to established or hypothesized molecular mechanisms and illustrated with images of classic examples and several potential emerging toxic effects. ©RSNA, 2017.
引用
- Chang ST, Menias CO, Lubner MG, et al. Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies. Radiographics. 2017. PMID: 28753381. doi:10.1148/rg.2017160162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。